Opioid-Related Disorders
Conditions
Brief summary
The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence.
Interventions
DRUGBuprenorphine/naloxone
Sponsors
National Institute on Drug Abuse (NIDA)
Study design
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
Males/Females ages 21-50, opiate dependence according to DSM-IV criteria, self-reported use within the last 30 days, agreeable to conditions of study and signed informed consent
Exclusion criteria
Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or nursing women, dependence on etoh or benzodiazepines or other sedative-hypnotics, acute hepatitis, other medical conditions that deem participation to be unsafe.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Withdrawal symptoms | — |
| Opiate use | — |
| Opiate craving | — |
Countries
United States
Outcome results
None listed